How GcMAF therapy and Nagalase testing work together in treating cancer

Top Curve image

How GcMAF therapy and Nagalase testing work together in treating cancer

Macrophage cells are a specific type of white blood cell whose job it is to kill cancer cells.

Tumor cells release an enzyme known as Nagalase.  Nagalase degrades GCProtein to the point it is unable to become GcMAF . This is a problem because it inhibits the effectiveness of the body to fight cancer.

Since GcMAF only lives for about a week in the body, without continuous conversion of GcProtein, the stores of GcMAF are depleted rapidly in the presence of the enzyme Nagalase.  However, Nagalase can only destroy GcProtein and not GcMAF.

What does this mean?

It means that the body cannot make its’ own GcMAF. Thus, the introduction of external GcMAF through injection into the body has been shown to be effective. This keeps the Macrophage cell activity against the cancer cells optimal.

At Reno Integrative Medical Center , we utilize a blood test that can monitor the level of Nagalase in the body.  This is helpful to evaluate success of treatment.

Bobsphotosized  

Dr. Bob Eslinger at Reno Integrative Medical Center

Add Your Comment

5 + 7 =